Evidence map›Paper›PMID 39052085›Full record

ArticleJournal of cancer research and clinical oncology2024

The use of peripheral CD3

Shuhan Zhang, Luyang Li, Chengli Liu, Meng Pu, Yingbo Ma, Tao Zhang, Jiaqi Chai, Haoming Li, Jun Yang, Meishan Chen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shuhan Zhang *Department of Hepatobiliary Surgery, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-9697-7320
Luyang Li *Postgraduate Training Base of Air Force Medical Center, China Medical University, Beijing, China.ORCID http://orcid.org/0000-0003-4768-449X
Chengli Liu *Department of Hepatobiliary Surgery, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China. liuchengli_beijing@163.com.ORCID http://orcid.org/0000-0002-9654-7486
Meng PuDepartment of Hepatobiliary Surgery, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-4048-5976
Yingbo MaDepartment of Hepatobiliary Surgery, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China.ORCID http://orcid.org/0000-0001-9550-1622
Tao ZhangDepartment of Hepatobiliary Surgery, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-9532-5371
Jiaqi ChaiDepartment of Colorectal Surgery, 731 Hospital of China Aerospace Science and Industry group, Beijing, China.ORCID http://orcid.org/0009-0007-9885-7561
Haoming LiPostgraduate Training Base of Air Force Medical Center, China Medical University, Beijing, China.ORCID http://orcid.org/0000-0003-4491-2557
Jun YangPostgraduate Training Base of Air Force Medical Center, China Medical University, Beijing, China.ORCID http://orcid.org/0000-0003-3722-3833
Meishan ChenDepartment of Ultrasound, Strategic Support Force Xingcheng Specialized Sanatorium, Huludao, China.ORCID http://orcid.org/0009-0009-6894-5821
Linghong KongDepartment of Hepatobiliary Surgery, Air Force Medical Center, PLA, Air Force Medical University, Beijing, China.ORCID http://orcid.org/0000-0002-0219-6655
Tian XiaGraduate School of Hebei North University, Zhangjiakou, China.ORCID http://orcid.org/0009-0000-9155-2430

Funding

Clinical research project of Air Force Medical Center 2021LC013
6 · The paper itself

Abstract

backgroundCurrently, there is a lack of effective indicators for predicting the efficacy of immunotherapy in patients with advanced hepatocellular carcinoma (HCC). This study aimed to investigate the expression and prognostic value of peripheral T lymphocyte subsets in advanced HCC.

methodsPatients with advanced HCC who were treated with immune checkpoint inhibitors (ICIs) from December 2021 to December 2023 were included in the study. Flow cytometry was used to detect lymphocyte subsets before treatment. The patients were divided into disease control (DC) and nondisease control (nDC) groups based on treatment efficacy. Relationships between the clinical characteristics/peripheral T lymphocytes and immunotherapy efficacy were analyzed. The effectiveness of peripheral T lymphocyte subsets in predicting immunotherapy efficacy for patients with advanced HCC was analyzed using receiver operating characteristic (ROC) curves.

resultsA total of 40 eligible patients were included in this study. Non-DC was significantly associated with higher albumin-bilirubin (ALBI) scores. The percentages of γδ

conclusionsThe calculation of the ALBI score and determination of the percentages CD3

Indexed as

Carcinoma, HepatocellularImmune Checkpoint InhibitorsImmunotherapyLiver NeoplasmsAdultAgedCD3 ComplexFemaleHumansMaleMiddle AgedPrognosisReceptors, Antigen, T-Cell, gamma-deltaRetrospective StudiesT-Lymphocyte SubsetsCD3 ComplexImmune Checkpoint InhibitorsReceptors, Antigen, T-Cell, gamma-deltaHepatocellular carcinomaImmunotherapyT lymphocyte subsetsΓδ T cell

Identifiers

PMID39052085
PMCPMC11272815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.